[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SE9701398D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
SE9701398D0
SE9701398D0 SE9701398A SE9701398A SE9701398D0 SE 9701398 D0 SE9701398 D0 SE 9701398D0 SE 9701398 A SE9701398 A SE 9701398A SE 9701398 A SE9701398 A SE 9701398A SE 9701398 D0 SE9701398 D0 SE 9701398D0
Authority
SE
Sweden
Prior art keywords
pct
date
novel compounds
sec
pub
Prior art date
Application number
SE9701398A
Other languages
English (en)
Inventor
David Cheshire
Martin Cooper
David Donald
Philip Thorne
Original Assignee
Astra Pharma Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Pharma Prod filed Critical Astra Pharma Prod
Priority to SE9701398A priority Critical patent/SE9701398D0/sv
Publication of SE9701398D0 publication Critical patent/SE9701398D0/sv
Priority to SK1356-99A priority patent/SK135699A3/sk
Priority to PCT/SE1998/000640 priority patent/WO1998046606A1/en
Priority to EEP199900465A priority patent/EE9900465A/xx
Priority to EP98917859A priority patent/EP0975636B1/en
Priority to IDW991207A priority patent/ID22746A/id
Priority to CN98806075A priority patent/CN1259951A/zh
Priority to BR9808540-9A priority patent/BR9808540A/pt
Priority to IL13215398A priority patent/IL132153A0/xx
Priority to PL98336230A priority patent/PL336230A1/xx
Priority to KR1019997009435A priority patent/KR20010006350A/ko
Priority to AU70909/98A priority patent/AU733066B2/en
Priority to AT98917859T priority patent/ATE245648T1/de
Priority to HU0002104A priority patent/HUP0002104A3/hu
Priority to JP54380398A priority patent/JP2001520645A/ja
Priority to DE69816608T priority patent/DE69816608T2/de
Priority to CA002286078A priority patent/CA2286078A1/en
Priority to TR1999/02538T priority patent/TR199902538T2/xx
Priority to US09/068,304 priority patent/US6028074A/en
Priority to IS5198A priority patent/IS5198A/is
Priority to NO995006A priority patent/NO995006L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)
SE9701398A 1997-04-15 1997-04-15 Novel compounds SE9701398D0 (sv)

Priority Applications (21)

Application Number Priority Date Filing Date Title
SE9701398A SE9701398D0 (sv) 1997-04-15 1997-04-15 Novel compounds
TR1999/02538T TR199902538T2 (xx) 1997-04-15 1998-04-07 Yeni bile�imler.
IL13215398A IL132153A0 (en) 1997-04-15 1998-04-07 Novel compounds
KR1019997009435A KR20010006350A (ko) 1997-04-15 1998-04-07 신규 화합물
EEP199900465A EE9900465A (et) 1997-04-15 1998-04-07 Uued ühendid
EP98917859A EP0975636B1 (en) 1997-04-15 1998-04-07 1h-pyrazolo[3,4-d]pyrimidine-4,6-diones as t-cell proliferation inhibitors
IDW991207A ID22746A (id) 1997-04-15 1998-04-07 Senyawa-senyawa baru
CN98806075A CN1259951A (zh) 1997-04-15 1998-04-07 新化合物
BR9808540-9A BR9808540A (pt) 1997-04-15 1998-04-07 Composto, processo para a preparação do mesmo, composição farmacêutica e processo para preparação dos mesmos, uso de um composto, e, processo para produzir a imunossupressão
SK1356-99A SK135699A3 (en) 1997-04-15 1998-04-07 Pyrazolo[3,4-d]pyrimidinedione compounds, preparation method thereof, pharmaceutical composition containing them and their use
PL98336230A PL336230A1 (en) 1997-04-15 1998-04-07 Novel chemical compounds
PCT/SE1998/000640 WO1998046606A1 (en) 1997-04-15 1998-04-07 Novel compounds
AU70909/98A AU733066B2 (en) 1997-04-15 1998-04-07 Novel compounds
AT98917859T ATE245648T1 (de) 1997-04-15 1998-04-07 1h-pyrazolo(3,4-d)pyrimidine-4,6-dione als inhibitoren für die vermehrung von t-zellen
HU0002104A HUP0002104A3 (en) 1997-04-15 1998-04-07 Pyrazolo[3,4-d]pyrimidinedione derivatives, process for their preparation and pharmaceutical compositions containing them
JP54380398A JP2001520645A (ja) 1997-04-15 1998-04-07 新規な化合物
DE69816608T DE69816608T2 (de) 1997-04-15 1998-04-07 1h-pyrazolo[3,4-d]pyrimidine-4,6-dione als inhibitoren für die vermehrung von t-zellen
CA002286078A CA2286078A1 (en) 1997-04-15 1998-04-07 Novel compounds
US09/068,304 US6028074A (en) 1997-04-15 1998-08-07 Pyrazolo[3,4-d]pyrimidineone compounds
IS5198A IS5198A (is) 1997-04-15 1999-09-27 Ný efnasambönd
NO995006A NO995006L (no) 1997-04-15 1999-10-14 Nye forbindelser

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9701398A SE9701398D0 (sv) 1997-04-15 1997-04-15 Novel compounds

Publications (1)

Publication Number Publication Date
SE9701398D0 true SE9701398D0 (sv) 1997-04-15

Family

ID=20406576

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9701398A SE9701398D0 (sv) 1997-04-15 1997-04-15 Novel compounds

Country Status (21)

Country Link
US (1) US6028074A (sv)
EP (1) EP0975636B1 (sv)
JP (1) JP2001520645A (sv)
KR (1) KR20010006350A (sv)
CN (1) CN1259951A (sv)
AT (1) ATE245648T1 (sv)
AU (1) AU733066B2 (sv)
BR (1) BR9808540A (sv)
CA (1) CA2286078A1 (sv)
DE (1) DE69816608T2 (sv)
EE (1) EE9900465A (sv)
HU (1) HUP0002104A3 (sv)
ID (1) ID22746A (sv)
IL (1) IL132153A0 (sv)
IS (1) IS5198A (sv)
NO (1) NO995006L (sv)
PL (1) PL336230A1 (sv)
SE (1) SE9701398D0 (sv)
SK (1) SK135699A3 (sv)
TR (1) TR199902538T2 (sv)
WO (1) WO1998046606A1 (sv)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801399D0 (sv) 1998-04-21 1998-04-21 Astra Pharma Prod Method and apparatus for filling containers
GC0000177A (en) 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
JP2004527541A (ja) 2001-03-01 2004-09-09 スミスクライン・ビーチャム・コーポレイション トロンボポエチン模倣物
US20030211040A1 (en) 2001-08-31 2003-11-13 Paul Greengard Phosphodiesterase activity and regulation of phosphodiesterase 1B-mediated signaling in brain
MY142390A (en) 2002-05-22 2010-11-30 Glaxosmithkline Llc 3' - [(2z)-[1-(3,4-dimethylphenyl)-1,5- dihydro-3- methyl-5-0xo-4h-pyrazol-4- ylidene]hydrazino]-2' -hydroxy -[1,1' -biphenyl]-3-carboxylic acid bis-(monoethanolamine)
TW200526638A (en) 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
WO2006127918A2 (en) * 2005-05-24 2006-11-30 Ott David M Personal care and medicinal products incorporating bound organosulfur groups
BRPI0611095B8 (pt) 2005-06-06 2021-05-25 Intracellular Therapies Inc compostos inibidores de pde1, composição farmacêutica compreendendo-os, usos dos mesmos como inibidores de pde1 para o tratamento de doenças relacionadas, tal como doença de parkinson e deficiência cognitiva, e métodos para produção dos ditos compostos
US9255099B2 (en) 2006-06-06 2016-02-09 Intra-Cellular Therapies, Inc. Pyrazolo[3,4-D]pyrimidine-4,6(5H,7H)-diones as phosphodiesterase 1 inhibitors
WO2008063505A1 (en) 2006-11-13 2008-05-29 Intra-Cellular Therapies, Inc. Organic compounds
EP2089034A4 (en) 2006-12-05 2010-07-28 Intra Cellular Therapies Inc NEW USES
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
SI2240490T1 (sl) 2007-12-06 2014-02-28 Takeda Pharmaceutical Company Limited Organske spojine
MX2010006208A (es) * 2007-12-06 2010-12-21 Intra Cellular Therapies Inc Compuestos organicos.
US8664207B2 (en) 2008-12-06 2014-03-04 Intra-Cellular Therapies, Inc. Organic compounds
AU2009322899A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
WO2010065152A1 (en) * 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
JP5778582B2 (ja) 2008-12-06 2015-09-16 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
ES2544976T3 (es) 2008-12-06 2015-09-07 Intra-Cellular Therapies, Inc. Compuestos de 4,5,7,8-tetrahidro-2H-imidazo[1,2-a]pirrolo[3,4-e]pirimidina como inhibidores de la PDE1
GEP20146029B (en) 2008-12-06 2014-02-10 Intracellular Therapies Inc Organic compounds
WO2010098839A1 (en) 2009-02-25 2010-09-02 Intra-Cellular Therapies, Inc. Pde 1 inhibitors for ophthalmic disorders
BRPI1013559A2 (pt) * 2009-03-23 2016-04-12 Glenmark Pharmaceuticals Sa compostos, composição farmacêutica, método de tratamento de doença ou condição associada à função trpa1 e respectivos usos
WO2010109328A1 (en) 2009-03-23 2010-09-30 Glenmark Pharmaceuticals, S.A. Isothiazolo-pyrimidinedione derivatives as trpa1 modulators
US8623880B2 (en) 2009-03-23 2014-01-07 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as TRPA1 modulators
BRPI1013705A2 (pt) 2009-03-23 2016-04-05 Glenmark Pharmaceuticals Sa compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica
WO2010132127A1 (en) 2009-05-13 2010-11-18 Intra-Cellular Therapies, Inc. Organic compounds
KR20120015355A (ko) 2009-05-29 2012-02-21 글락소스미스클라인 엘엘씨 트롬보포이에틴 효능제 화합물의 투여 방법
EP2461673A4 (en) 2009-08-05 2013-08-07 Intra Cellular Therapies Inc NEW REGULATOR PROTEINS AND HEMMER
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
WO2011153138A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
JP5894148B2 (ja) 2010-05-31 2016-03-23 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
WO2011153136A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
US10561656B2 (en) 2011-06-10 2020-02-18 Intra-Cellular Therapies, Inc. Organic compounds
JP5989900B2 (ja) 2012-06-08 2016-09-07 グレンマーク ファーマシューティカルズ， エセ．アー． ２−アミノ−４−アリールチアゾール化合物のアミド及びその塩類
EP2956141A4 (en) 2013-02-17 2016-10-26 Intra Cellular Therapies Inc NEW USES
JP2016518343A (ja) 2013-03-15 2016-06-23 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規使用
CN105377846B (zh) 2013-03-15 2018-03-20 细胞内治疗公司 有机化合物
JP6696904B2 (ja) 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 製剤および医薬組成物
ES2732442T3 (es) 2014-06-20 2019-11-22 Intra Cellular Therapies Inc Compuestos orgánicos
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
WO2016022893A1 (en) 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Organic compounds
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
MX2017003646A (es) 2014-09-17 2017-07-13 Intra Cellular Therapies Inc Compuestos y metodos.
JP6608933B2 (ja) 2014-12-06 2019-11-20 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
JP6608934B2 (ja) 2014-12-06 2019-11-20 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
JP2019510039A (ja) 2016-03-28 2019-04-11 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規組成物および方法
WO2018015088A1 (en) * 2016-06-23 2018-01-25 F. Hoffmann-La Roche Ag Novel [1,2,31triazolo[4,5-d]pyrimidine derivatives
ES2906107T3 (es) 2016-09-12 2022-04-13 Intra Cellular Therapies Inc Usos novedosos
JP7401442B2 (ja) 2018-01-31 2023-12-19 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58500966A (ja) * 1981-04-22 1983-06-09 ビイク　グルデン　ロンベルク　ヒエ−ミツシエ　フアブリ−ク　ゲゼルシヤフト　ミツト　ベシユレンクテル　ハフツング 新規ピラゾロ〔３，４−ｄ〕ピリミジン、その製法及びこれを含有する医薬品
US4603203A (en) * 1983-12-14 1986-07-29 Takeda Chemical Industries, Ltd. 3-aminopyrazolo[3,4-d]pyrimidine derivatives and production thereof
EP0237289A3 (en) * 1986-03-14 1988-07-27 Takeda Chemical Industries, Ltd. Pyrazolo [3,4-d] pyrimidine derivatives, their production and use
RU2142946C1 (ru) * 1992-12-17 1999-12-20 Пфайзер Инк. Производные пиразола и фармацевтическая композиция, содержащая их
TW444018B (en) * 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines

Also Published As

Publication number Publication date
EP0975636A1 (en) 2000-02-02
CN1259951A (zh) 2000-07-12
IL132153A0 (en) 2001-03-19
CA2286078A1 (en) 1998-10-22
TR199902538T2 (xx) 2000-02-21
DE69816608D1 (de) 2003-08-28
NO995006D0 (no) 1999-10-14
DE69816608T2 (de) 2004-04-15
BR9808540A (pt) 2000-05-23
US6028074A (en) 2000-02-22
IS5198A (is) 1999-09-27
ATE245648T1 (de) 2003-08-15
NO995006L (no) 1999-10-14
ID22746A (id) 1999-12-09
AU733066B2 (en) 2001-05-03
KR20010006350A (ko) 2001-01-26
AU7090998A (en) 1998-11-11
SK135699A3 (en) 2000-05-16
WO1998046606A1 (en) 1998-10-22
EP0975636B1 (en) 2003-07-23
HUP0002104A2 (hu) 2001-01-29
PL336230A1 (en) 2000-06-19
JP2001520645A (ja) 2001-10-30
EE9900465A (et) 2000-04-17
HUP0002104A3 (en) 2002-03-28

Similar Documents

Publication Publication Date Title
SE9701398D0 (sv) Novel compounds
EE200000318A (et) Uudsed ühendid
EE9900315A (et) Pürrolo[3,4-d]pürimidinooni derivaadid ja nende kasutamine ravimitena
SE9702001D0 (sv) Novel compounds
HUT75776A (en) Pyrazolo and pyrrolopyridines, their using, pharmaceutical compositions containing them and intermediates
ATE334668T1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
HUP0104318A2 (hu) cGMP PDE-5 inhibitort tartalmazó szabályzottan hatóanyagot felszabadító gyógyászati készítmények
SE9702772D0 (sv) Novel compounds
MXPA04003668A (es) Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
UA66801C2 (uk) Триазоло[4,5-d]піримідинові сполуки, спосіб їх одержання (варіанти), фармацевтична композиція на їх основі та спосіб лікування порушень агрегації тромбоцитів
MXPA02007942A (es) Derivados de pirrolopirimidinona, procesos de preparacion y uso.
SE9904129D0 (sv) Novel compounds
HK1075450A1 (en) heterocyclic compunds, process for their preparation and pharmaceutical compositions containing thenm and thier use in medicine
HUP0002346A1 (hu) Emlősök elmezavarainak kezelésére szolgáló gyógyszerkészítmény
HUP0100611A2 (hu) Triazin vegyületek, és ilyeneket tartalmazó gyógyszerkészítmények a központi idegrendszer elváltozásainak kezelésére
DE69911785D1 (de) Triazolo[4,5-d]pyrimidin-verbindungen
AU3862997A (en) Stable derivatives of ubiquinole, processes for their production and pharmaceutical use thereof
AU7436098A (en) Use of mizolastine for preparing a medicine for treating inflammation